Epstein-Barr Virus-infected Nasopharyngeal Carcinoma Therapeutics: Oncoprotein Targets and Clinical Implications

Overview

Journal Med Oncol

Publisher Springer

Date 2025 Jan 31

PMID 39888474

Authors

Jacqueline Kar Kei Mark

Aik-Hong Teh

Beow Keat Yap

Affiliations

Soon will be listed here.

Abstract

Nasopharyngeal carcinoma (NPC) is a distinctive epithelial cancer closely associated with Epstein-Barr Virus (EBV) infection, posing significant challenges in diagnosis and treatment due to its resistance to conventional therapies and high recurrence rates. Current therapies, including radiotherapy and chemotherapy, exhibit limited efficacy, particularly in recurrent or metastatic cases, highlighting the urgent need for novel therapeutic strategies. Targeting EBV oncoproteins, such as Epstein-Barr Virus encoded Nuclear Antigen 1 (EBNA1), Latent Membrane Protein 1 (LMP1), and Latent Membrane Protein 2 (LMP2), presents a promising therapeutic avenue in NPC treatment. This review discusses the latest advancements in drug discovery targeting EBV oncoproteins, emphasizing the identification of inhibitors for specific functional regions of oncoproteins EBNA1, LMP1, and LMP2. Particular attention is given to the molecular mechanisms of these inhibitors and their preclinical or clinical potential in treating EBV-positive NPC. These developments highlight a promising future for targeted therapies in improving outcomes for NPC patients.

References

Juarez-Vignon Whaley J, Afkhami M, Onyshchenko M, Massarelli E, Sampath S, Amini A . Recurrent/Metastatic Nasopharyngeal Carcinoma Treatment from Present to Future: Where Are We and Where Are We Heading?. Curr Treat Options Oncol. 2023; 24(9):1138-1166. PMC: 10477128. DOI: 10.1007/s11864-023-01101-3. View

Bossi P, Chan A, Licitra L, Trama A, Orlandi E, Hui E . Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020; 32(4):452-465. DOI: 10.1016/j.annonc.2020.12.007. View

Zealiyas K, Teshome S, Berhe N, Amogne W, Feleke Haile A, Abate E . The Burden of Epstein-Barr Virus (EBV) and Its Determinants among Adult HIV-Positive Individuals in Ethiopia. Viruses. 2023; 15(8). PMC: 10458830. DOI: 10.3390/v15081743. View

Nasimuzzaman M, Kuroda M, Dohno S, Yamamoto T, Iwatsuki K, Matsuzaki S . Eradication of Epstein-Barr virus episome and associated inhibition of infected tumor cell growth by adenovirus vector-mediated transduction of dominant-negative EBNA1. Mol Ther. 2005; 11(4):578-90. DOI: 10.1016/j.ymthe.2004.12.017. View

Gunven P, Klein G, Henle G, Henle W, Clifford P . Epstein-Barr virus in Burkitt's lymphoma and nasopharyngeal carcinoma. Antibodies to EBV associated membrane and viral capsid antigens in Burkitt lymphoma patients. Nature. 1970; 228(5276):1053-6. DOI: 10.1038/2281053a0. View

Wolf H, zur Hausen H, Klein G, Becker V, Henle G, Henle W . Attempts to detect virus-specific DNA sequences in human tumors. III. Epstein-Barr viral DNA in non-lymphoid nasopharyngeal carcinoma cells. Med Microbiol Immunol. 1975; 161(1):15-21. DOI: 10.1007/BF02120766. View

Yuan Y, Ye F, Wu J, Fu X, Huang Z, Zhang T . Early screening of nasopharyngeal carcinoma. Head Neck. 2023; 45(10):2700-2709. DOI: 10.1002/hed.27466. View

Richardo T, Prattapong P, Ngernsombat C, Wisetyaningsih N, Iizasa H, Yoshiyama H . Epstein-Barr Virus Mediated Signaling in Nasopharyngeal Carcinoma Carcinogenesis. Cancers (Basel). 2020; 12(9). PMC: 7565514. DOI: 10.3390/cancers12092441. View

Bruce J, To K, Lui V, Chung G, Chan Y, Tsang C . Whole-genome profiling of nasopharyngeal carcinoma reveals viral-host co-operation in inflammatory NF-κB activation and immune escape. Nat Commun. 2021; 12(1):4193. PMC: 8263564. DOI: 10.1038/s41467-021-24348-6. View

10.

Yang T, You C, Meng S, Lai Z, Ai W, Zhang J . EBV Infection and Its Regulated Metabolic Reprogramming in Nasopharyngeal Tumorigenesis. Front Cell Infect Microbiol. 2022; 12:935205. PMC: 9283984. DOI: 10.3389/fcimb.2022.935205. View

11.

Pei Y, Robertson E . The Central Role of the Ubiquitin-Proteasome System in EBV-Mediated Oncogenesis. Cancers (Basel). 2022; 14(3). PMC: 8833352. DOI: 10.3390/cancers14030611. View

12.

Png Y, Yang A, Lee M, Chua M, Lim C . The Role of NK Cells in EBV Infection and EBV-Associated NPC. Viruses. 2021; 13(2). PMC: 7918975. DOI: 10.3390/v13020300. View

13.

Yarza R, Bover M, Agullo-Ortuno M, Iglesias-Docampo L . Current approach and novel perspectives in nasopharyngeal carcinoma: the role of targeting proteasome dysregulation as a molecular landmark in nasopharyngeal cancer. J Exp Clin Cancer Res. 2021; 40(1):202. PMC: 8215824. DOI: 10.1186/s13046-021-02010-9. View

14.

Hau P, Lung H, Wu M, Tsang C, Wong K, Mak N . Targeting Epstein-Barr Virus in Nasopharyngeal Carcinoma. Front Oncol. 2020; 10:600. PMC: 7247807. DOI: 10.3389/fonc.2020.00600. View

15.

Valentine R, Dawson C, Hu C, Shah K, Owen T, Date K . Epstein-Barr virus-encoded EBNA1 inhibits the canonical NF-kappaB pathway in carcinoma cells by inhibiting IKK phosphorylation. Mol Cancer. 2010; 9:1. PMC: 2818691. DOI: 10.1186/1476-4598-9-1. View

16.

Messick T, Smith G, Soldan S, McDonnell M, Deakyne J, Malecka K . Structure-based design of small-molecule inhibitors of EBNA1 DNA binding blocks Epstein-Barr virus latent infection and tumor growth. Sci Transl Med. 2019; 11(482). PMC: 6936217. DOI: 10.1126/scitranslmed.aau5612. View

17.

Jourdan N, Jobart-Malfait A, Dos Reis G, Quignon F, Piolot T, Klein C . Live-cell imaging reveals multiple interactions between Epstein-Barr virus nuclear antigen 1 and cellular chromatin during interphase and mitosis. J Virol. 2012; 86(9):5314-29. PMC: 3347338. DOI: 10.1128/JVI.06303-11. View

18.

Wu H, Kapoor P, Frappier L . Separation of the DNA replication, segregation, and transcriptional activation functions of Epstein-Barr nuclear antigen 1. J Virol. 2002; 76(5):2480-90. PMC: 135949. DOI: 10.1128/jvi.76.5.2480-2490.2002. View

19.

Chakravorty A, Sugden B . The AT-hook DNA binding ability of the Epstein Barr virus EBNA1 protein is necessary for the maintenance of viral genomes in latently infected cells. Virology. 2015; 484:251-258. PMC: 4567472. DOI: 10.1016/j.virol.2015.05.018. View

20.

Norseen J, Johnson F, Lieberman P . Role for G-quadruplex RNA binding by Epstein-Barr virus nuclear antigen 1 in DNA replication and metaphase chromosome attachment. J Virol. 2009; 83(20):10336-46. PMC: 2753104. DOI: 10.1128/JVI.00747-09. View